Hallucinogen Toxicity Clinical Presentation
- Author: Joseph A Salomone III, MD; Chief Editor: Asim Tarabar, MD more...
History
Although most patients who present to the ED with hallucinogen intoxication have a history of recent ingestion, not all are diagnosed easily.[7]
Consider possible hallucinogen ingestion in patients with acute psychotic behavior and attempt to trace the onset and causes of the behavior.
A history of previous hallucinogen abuse may indicate acute ingestion, flashback behavior, or psychotic break caused by the abuse.
Make an effort to screen patients for other potential exposures or ingestions as well as infectious, traumatic, or other underlying etiologies of the behavior.
Question family, friends, and prehospital care personnel closely for clues to possible etiology of the behavior.
Lysergic acid diethylamide
Patients presenting for ED care are generally those for whom the hallucinogenic experiences have become uncomfortable (ie, "bad trips") or those who have become injured or appear at risk for self-injury because of their behavior. Initial evaluation may reveal a patient who is agitated and psychotic.
The patient may be confused or disoriented, display distorted perceptions and impaired judgment, and have impaired concentration and intellectual functions. Physical examination may reveal mydriasis, tachycardia, and tachypnea without any other significant physical findings. Examine the patient thoroughly for traumatic injuries and the possibility of other etiologies, such as CNS infections or other acute intoxication. Laboratory evaluation may include urine drug assays, urinalysis, and blood glucose. Perform additional testing if etiology of the behavior is in doubt.
Phencyclidine and ketamine
Individuals who ingest these substances often have been found in bizarre situations or have placed themselves in danger. The dissociative properties of these drugs allow the abusers to believe they are outside of their body, and the anesthetic properties prevent normal pain feedback mechanisms that usually limit physical activity.
Individuals with significant intoxication can sustain tremendous and even life-threatening injuries without perceived pain. They often fluctuate from combative and anxious to sedated and somnolent. Patients generally have mixed nystagmus, comprising horizontal, vertical, and rotatory. Rotatory nystagmus strongly suggests PCP intoxication.
Most patients have mild-to-moderate hypertension and approximately one third have tachycardia. Confusion, altered perceptions, visual hallucinations, and significant violent or self-destructive behavior may occur. The period of psychotic behavior may be prolonged, with episodes of severe depression and schizophrenia.
Psilocin and psilocybin
The most common effects are perceptual distortions or hallucinations. Hallucinations are generally visual but other types may occur. Some patients experience euphoria and tachycardia, and most patients have some mydriasis. Hyperreflexia, anxiety, and drowsiness may occur.
Some species of toxic mushrooms may cause adverse GI reactions, including cramping, nausea and vomiting, and diarrhea. Always consider the possibility of toxic mushroom ingestion in patients presenting with a history of mushroom use.
Mescaline
Initial responses include agitation, diaphoresis, and abdominal cramping with nausea and vomiting. Initially, mildly elevated blood pressure with reflex bradycardia and mildly elevated body temperature may occur. Larger ingestions can produce hypotension and respiratory depression. Often the individual ritualistically collects and re-ingests the vomited material to maximize the hallucinogenic effect. These adverse effects generally persist for only 1-2 hours.
Feelings of euphoria and associated hallucinations generally begin 2-4 hours postingestion. The sympathomimetic effects may persist throughout the intoxication. Hallucinations are mostly visual, but all forms may occur. A sense of expansion of self and tremendous power has been described, with associated intense visual images in bright colors and geometric patterns. Adverse perceptions of self, anxiety, and depression can occur. The intoxication generally lasts 6-8 hours and usually is followed by somnolence.
Patients presenting after mescaline ingestion often complain of the sympathomimetic effects and GI distress associated with the ingestion. Although physical injury can occur because of the dysphoria and sense of power, this is less common than with PCP.
Designer drugs
The amphetamine -derived designer drugs all have sympathomimetic effects that account for the adverse effects (eg, hypertension, tachycardia, hyperthermia).[8] Hyperthermia may be the most serious adverse effect, and it may be compounded by the use as "club drugs" or at "raves" where use is associated with prolonged dancing and dehydration. The prolonged dancing or other physical activity may contribute to the severe hyperthermia that has been described, and this as well as the dehydration may contribute to associated rhabdomyolysis[9] and renal failure. Hypertensive crisis has also been described.
Effects last from a few hours to as long as 24 hours for drugs like AMT.
Seizures may occur.
Physical
- Patient presentations may vary from appearing anxious and agitated to somnolent or sedated.
- Mydriasis is often present, particularly with LSD use.
- Tachycardia, tachypnea, and mild-to-moderate elevation of blood pressure often are noted.
- Temperature generally is normal, but a patient experiencing episodes of extreme exertion, combative behavior, or infection may present with hyperthermia.
- The neurologic examination should be nonfocal, with varying degrees of cognitive distortions or deficits.
- Traumatic injuries may be present and may be caused by the altered perceptions of reality or combative or destructive behavior.
Grundmann O, Phipps SM, Zadezensky I, Butterweck V. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology. Planta Med. Aug 2007;73(10):1039-46. [Medline].
Brown DJ. Salvia on Schedule: Law, Medicine and a Hallucinogen. Sci Am [serial online]. August 2009;Accessed September 9, 2009. Available at http://www.scientificamerican.com/article.cfm?id=salvia-on-schedule.
Schilt T, de Win MM, Koeter M, Jager G, Korf DJ, van den Brink W. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry. Jun 2007;64(6):728-36. [Medline].
Verrico CD, Miller GM, Madras BK. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl). Jan 2007;189(4):489-503. [Medline].
Wu LT, Ringwalt CL, Weiss RD, Blazer DG. Hallucinogen-related disorders in a national sample of adolescents: the influence of ecstasy/MDMA use. Drug Alcohol Depend. Sep 1 2009;104(1-2):156-66. [Medline].
Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future: National survey results on drug use, 1975-2007: Volume II, College students and adults ages 19-45. Bethesda, MD: National Institute of Drug Abuse; October 2008. 319.
Nicholson TC. Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department. Emerg Med Australas. Apr 2006;18(2):180-4. [Medline].
Liechti ME, Kunz I, Kupferschmidt H. Acute medical problems due to Ecstasy use. Case-series of emergency department visits. Swiss Med Wkly. Oct 29 2005;135(43-44):652-7. [Medline].
Alatrash G, Majhail NS, Pile JC. Rhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivative. Mayo Clin Proc. Apr 2006;81(4):550-1. [Medline].
Dumont GJ, Kramers C, Sweep FC, Touw DJ, van Hasselt JG, de Kam M, et al. Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans. Clin Pharmacol Ther. Aug 2009;86(2):160-6. [Medline].
Barone JA, Shermock KM. Designer drugs of abuse. J Pharm Pract. 1997;10(4):292-300.
Berger KJ, Guss DA. Mycotoxins revisited: Part II. J Emerg Med. Feb 2005;28(2):175-83. [Medline].
Bücheler R, Gleiter CH, Schwoerer P, Gaertner I. Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). Pharmacopsychiatry. Jan 2005;38(1):1-5. [Medline].
Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med. Jul 1994;24(1):68-76. [Medline].
Caravati EM. Hallucinogenic drugs. In: Medical Toxicology. 3rd ed. 2004:1103-1111.
Clemens KJ, McGregor IS, Hunt GE, Cornish JL. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Drug Alcohol Rev. Jan 2007;26(1):9-15. [Medline].
de la Torre R, Farre M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. Apr 2004;26(2):137-44. [Medline].
DEA Intelligence Division. Club Drugs: An Update. Drug Intelligence Brief. 2000 Sept.
DEA Intelligence Division. PCP: the threat remains. Drug Intelligence Brief. 2003 May.
DEA Intelligence Division. Trippin' on tryptamines: the emergence of foxy and AMT as drugs of abuse. Drug Intelligence Brief. 2002 Oct.
El-Mallakh RS, Abraham HD. MDMA (Ecstasy). Ann Clin Psychiatry. Jan-Mar 2007;19(1):45-52. [Medline].
Graeme KA. New drugs of abuse. Emerg Med Clin North Am. Nov 2000;18(4):625-36. [Medline].
Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther. May 2004;102(2):131-8. [Medline].
Hoppe-Roberts JM, Lloyd LM, Chyka PA. Poisoning mortality in the United States: comparison of national mortality statistics and poison control center reports. Ann Emerg Med. May 2000;35(5):440-8. [Medline].
Lai TI, Hwang JJ, Fang CC, Chen WJ. Methylene 3, 4 dioxymethamphetamine-induced acute myocardial infarction. Ann Emerg Med. Dec 2003;42(6):759-62. [Medline].
Leikin JB, Krantz AJ, Zell-Kanter M, et al. Clinical features and management of intoxication due to hallucinogenic drugs. Med Toxicol Adverse Drug Exp. Sep-Oct 1989;4(5):324-50. [Medline].
Lynton RC, Albertson TE. Amphetamines and designer drugs. In: Medical Toxicology. 3rd ed. 2004:1071-1083.
Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. Apr 2004;26(2):127-31. [Medline].
Mueller PD, Korey WS. Death by "ecstasy": the serotonin syndrome?. Ann Emerg Med. Sep 1998;32(3 Pt 1):377-80. [Medline].
National Advisory Council on Drug Abuse. Director's Report to the National Advisory Council on Drug Abuse. May 1997;1-21.
Parrott AC. MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology. 2004;50(4):329-35. [Medline].
Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. Oct 2002;7(4):357-64. [Medline].
Reid LW, Elifson KW, Sterk CE. Hug drug or thug drug? Ecstasy use and aggressive behavior. Violence Vict. 2007;22(1):104-19. [Medline].
Richardson WH 3rd, Slone CM, Michels JE. Herbal drugs of abuse: an emerging problem. Emerg Med Clin North Am. May 2007;25(2):435-57; abstract ix. [Medline].
Schwartz RH. LSD. Its rise, fall, and renewed popularity among high school students. Pediatr Clin North Am. Apr 1995;42(2):403-13. [Medline].
Staak RF. Piperazine designer drugs of abuse. Lancet. Apr 2007;369:1412-1413.
Yan F, Roth BL. Salvinorin A: a novel and highly selective kappa-opioid receptor agonist. Life Sci. Oct 15 2004;75(22):2615-9. [Medline].

